This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February
by Arpita Dutt
Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.
Surging Earnings Estimates Signal Good News for BioMarin Pharmaceutical (BMRN)
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
What Drives Catalyst Pharmaceuticals Above 250% This Year?
by Zacks Equity Research
We take a look at the factors that drive phenomenal growth in Catalyst Pharmaceuticals' (CPRX) share price in 2017.
Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo
by Arpita Dutt
A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.
BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA
by Zacks Equity Research
BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.
BioMarin's (BMRN) Gene Therapy Enters First Phase III Study
by Zacks Equity Research
BioMarin (BMRN) commences the first phase III study to evaluate the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.
Spark Therapeutics Stock Plunges on Hemophilia Therapy Data
by Zacks Equity Research
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Here's Why Sarepta Stock is Up More Than 70% in 6 Months
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.
Catalyst (CPRX) Reports Positive Phase III Data on Firdapse
by Zacks Equity Research
Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.
Catalyst Initiates Phase II Study for Pipeline Drug Firdapse
by Zacks Equity Research
Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
by Zacks Equity Research
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.
BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised
by Zacks Equity Research
BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.
Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised
by Zacks Equity Research
Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.
What's in Store for BioMarin (BMRN) This Earnings Season?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
by Zacks Equity Research
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
Here's Why Sarepta Stock is Up More Than 60% So Far in 2017
by Zacks Equity Research
Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
by Arpita Dutt
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA
by Zacks Equity Research
The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.
BioMarin Presents Interim Data on BMN 250 from Phase I/II
by Zacks Equity Research
BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.
Sarepta's Golodirsen Positive in DMD Study, Shares Soar
by Zacks Equity Research
Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.
BioMarin (BMRN) Up 2.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
BioMarin (BMRN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stock Market News For August 31, 2017
by Zacks Equity Research
Stock market closed higher on Wednesday following a couple of bullish economic reports, even as the S&P 500 notched up a four-day winning streak.
BioMarin (BMRN) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
BioMarin (BMRN) shares rose nearly 6% in the last trading session, amid huge volumes.
Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update
by Arpita Dutt
It's all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.